VivoSeq
Ophthalmology

Diabetic Retinopathy

83

Pipeline Programs↗

14

Active Trials↗

31

Companies Involved↗

Diabetic Retinopathy is a moderately active landscape with 83 programs across 31 companies. The most active players are Shenzhen MingSight Relin Pharmaceuticals Co., Ltd., Javelin Pharmaceuticals, Intec Pharma Ltd.. 17 therapies are approved with 19 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

19/100

Mech. Concentration

14/100

Completion Rate

87/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

1 program

Phase 1J

Javelin Pharmaceuticals

1 program

Phase 1I

Intec Pharma Ltd.

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

3 programs

Phase 2O

OcuTerra Therapeutics, Inc.

1 program

Phase 2C

Chengdu Kanghong Pharmaceutical Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical16

Finerenone

Bayer

Eylea

Bayer

Aflibercept

Regeneron

Ranibizumab

Roche

Avastin

Roche

Phase 112

Anecortave Acetate

Alcon Research

Triamcinolone Acetonide

Bausch Health Americas, Inc.

Ketorolac

Javelin Pharmaceuticals

Propranolol

Wyeth-Lederle Vaccines

Ro7663498

Roche

Phase 219

Levodopa

Merz Pharmaceuticals GmbH

Brimonidine

Novartis

Prednisolone Acetate

Novartis

Insulin

Merck & Co.

Doxycycline Monohydrate

Par Pharmaceutical, Inc.

Phase 319

Octreotide Acetate

Novartis

Bevacizumab

Bio-Thera Solutions

Aspirin

Bayer

Triamcinolone and Bevacizumab

Johann Wolfgang Goethe University Hospital

Melatonin

Neurim Pharmaceuticals Ltd.

Approved17

Triamcinolone

Bassett Healthcare

Fenofibrate

Jagotec

Captopril

Standard Chem. & Pharm. Co., Ltd.

Dexamethasone

Aspen Global Incorporated

Metformin

EMD Serono

Analysis

Modality Breakdown

90%

Small molecule

80 of 89 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody67%Protein / enzyme22%Cell therapy11%

Small molecule leads; the ring shows all 89 classified programs, each share of the total. Modality classified for 92% of 100 pipeline programs.

Analysis

Trial Status

89

clinical trials

Completed53 · 60%
Unknown status14 · 16%
Terminated7 · 8%
Recruiting6 · 7%
Active, not recruiting5 · 6%
Not yet recruiting2 · 2%
Other2 · 2%

Clinical Trials

Trial Activity

89 trials

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
Recruiting·UUniversity of Alabama at Birmingham·N/A·NCT03403699·20 enrolled
Sleep, Diabetic Retinopathy and Melatonin
Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT04547439·42 enrolled
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
Recruiting·UUniversity of Alabama at Birmingham·N/A·NCT03403686·104 enrolled
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
Recruiting·SShenzhen MingSight Relin Pharmaceuticals Co., Ltd.·Phase 1·NCT04187443·45 enrolled
An Operationally Seamless Phase 2b/3, Multicenter, Randomized, Masked, Sham-controlled Study to Evaluate the Efficacy and Safety of Surabgene Lomparvovec (Sura-vec) Delivered Via Suprachoroidal Space (SCS) Injection Targeting Subjects With Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema (CI-DME) (NAAVIGATE)
Recruiting·AbbVie logoAbbVie·Preclinical·NCT07592273·576 enrolled
A Multicenter, Non-Randomized, Open-Label, Multiple-Ascending-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy
Recruiting·Roche logoRoche·Phase 1·NCT07588100·30 enrolled
A Study of PER-001 in Participants With Diabetic Retinopathy
Active, not recruiting·PPerfuse Therapeutics, Inc.·Phase 2·NCT06003751·24 enrolled
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
Active, not recruiting·—·Phase 2·NCT05393284·114 enrolled
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
Active, not recruiting·KKodiak Sciences Inc·Phase 3·NCT06270836·255 enrolled
CRIMSON: A Multicentre, Randomised, Sham-controlled (and Active Controlled in the USA), Double-masked, 72-week Trial to Study the Safety, Tolerability, Pharmacokinetics, and Efficacy of 3 Dosing Regimens of Intravitreal BI 764524 in Patients With Moderate to Severe Non-proliferative Diabetic Retinopathy
Active, not recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT06321302·190 enrolled
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening
Active, not recruiting·JJaeb Center for Health Research·Phase 3·NCT04661358·563 enrolled
Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy
Not yet recruiting·—·Phase 4·NCT06660940·460 enrolled
Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy
Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT07236645·200 enrolled
Treating Early Stage Diabetic Retinopathy
Enrolling by invitation·VVA Office of Research and Development·Phase 1·NCT05132660·244 enrolled
Preoperative Topic Diclofenac as a Prevention of Postoperative Macular Edema in Patients With Diabetic Retinopathy
Completed·EEye Clinic Medic Zuljan Jukic·N/A·NCT01694212·55 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)